John B. Porter
UCL Cancer Institute
Department of Haematology
University College London
72 Huntley Street
UK
Name/email consistency: high
- Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Porter, J.B., Elalfy, M.S., Taher, A.T., Aydinok, Y., Chan, L.L., Lee, S.H., Sutcharitchan, P., Habr, D., Martin, N., El-Beshlawy, A. Ann. Hematol. (2013)
- Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Aydinok, Y., Evans, P., Manz, C.Y., Porter, J.B. Haematologica (2012)
- Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Porter, J.B., Lin, K.H., Beris, P., Forni, G.L., Taher, A., Habr, D., Domokos, G., Roubert, B., Thein, S.L. Eur. J. Haematol. (2011)
- Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Porter, J.B., Shah, F.T. Hematol. Oncol. Clin. North Am. (2010)
- Deferasirox--current knowledge and future challenges. Porter, J.B. Ann. N. Y. Acad. Sci. (2010)
- Optimizing iron chelation strategies in beta-thalassaemia major. Porter, J.B. Blood Rev. (2009)
- Deferasirox: an update. Porter, J.B. Hemoglobin (2009)
- Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Porter, J., Galanello, R., Saglio, G., Neufeld, E.J., Vichinsky, E., Cappellini, M.D., Olivieri, N., Piga, A., Cunningham, M.J., Soulières, D., Gattermann, N., Tchernia, G., Maertens, J., Giardina, P., Kwiatkowski, J., Quarta, G., Jeng, M., Forni, G.L., Stadler, M., Cario, H., Debusscher, L., Della Porta, M., Cazzola, M., Greenberg, P., Alimena, G., Rabault, B., Gathmann, I., Ford, J.M., Alberti, D., Rose, C. Eur. J. Haematol. (2008)
- Concepts and goals in the management of transfusional iron overload. Porter, J.B. Am. J. Hematol. (2007)
- Deferasirox: An effective once-daily orally active iron chelator. Porter, J.B. Drugs. Today (2006)
- Monitoring and treatment of iron overload: state of the art and new approaches. Porter, J.B. Semin. Hematol. (2005)
- Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T., Evans, P. Ann. N. Y. Acad. Sci. (2005)
- Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Porter, J.B., Davis, B.A. Best. Pract. Res. Clin. Haematol (2002)
- Practical management of iron overload. Porter, J.B. Br. J. Haematol. (2001)
- A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Porter, J.B., Faherty, A., Stallibrass, L., Brookman, L., Hassan, I., Howes, C. Ann. N. Y. Acad. Sci. (1998)
- A risk-benefit assessment of iron-chelation therapy. Porter, J.B. Drug. Saf (1997)